- Home
- HCAC vs AMRN Comparison
HCAC vs AMRN Comparison
Compare HCAC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.05
HOLD
Current Price
$14.89
Company Overview
Basic Information| Metric | HCAC | AMRN |
|---|---|---|
| Founded | 2025 | 1989 |
| Country | Singapore | Ireland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.7M | 342.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | HCAC | AMRN |
|---|---|---|
| Price | $10.05 | $14.89 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 76.7K | ★ 83.3K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $9.92 | $12.96 |
| 52 Week High | $10.08 | $20.90 |
Technical Indicators
Market Signals| Indicator | HCAC | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 41.75 |
| Support Level | N/A | $14.76 |
| Resistance Level | $10.06 | $15.09 |
| Average True Range (ATR) | 0.01 | 0.80 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 66.67 | 9.43 |
Price Performance
Historical Comparison HCAC
AMRN
About HCAC Hall Chadwick Acquisition Corp Class A Ordinary Shares
Hall Chadwick Acquisition Corp is a blank check company.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.